G Protein-Coupled Receptors: Molecular Pharmacology from Academic Concept to Pharmaceutical Research

G Protein-Coupled Receptors: Molecular Pharmacology from Academic Concept to Pharmaceutical Research

Volumn , Issue , 2007, Pages 1-252

  Vauquelin, Georges ^a   von Mentzer, Bengt ^b  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891295931     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470516652     Document Type: Book

References (142)

1. Ahlquist R. (1948) A study of adrenotopic receptors. American Journal of Physiology, 153, 586-600.
2. Allgeier, A., Laugwitz, K.-L., Van Sande, J., Schultz, G. and Dumont, J. E. (1997) Multiple G protein coupling of the dog thyrotropin receptor. Molecular and Cellular Endocrinology, 127, 81-90.
3. Alt, A., Mcfadyen, I. J., Fan, C. D., Woods, J. H. and Traynor, J. R. (2001) Stimulation of Guanosine-5'-O-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of micro-opioid receptors and G protein. Journal of Pharmacology & Experimental Therapeutics, 298, 116-121.
4. Anderson, K. M., Murahashi, T., Dostal, D. E. and Peach, M. J. (1993) Morphological and biochemical analysis of angiotensin II internalization in cultured rat aortic smooth muscle cells. American Journal of Physiology-Cell Physiology, 264, C179-188.
5. Ariens, E. J. (1954) Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Archives Internationales de Pharmacodynamie et de Therapie, 99, 32-49.
6. Arranz, M. J., Munro, J., Sham, P., Kirov, G., Murray, R. M., Collier, D. A. and Kerwin, R. W. (1998) Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophrenia Research, 32, 93-99.
7. Arunlakshana, O. and Schild, H. O. (1959) Some quantitative uses of drug antagonists. British Journal of Pharmacology and Chemotherapy, 14, 48-58.
8. Ballesteros, J.A. and Weinstein, W. H. (1995) Integrated methods for the construction of threedimensional models and computational probing of structure-function relations in G proteincoupled receptors. Methods in Neuroscience, 153, 586-600.
9. Berg, K. A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P. and Clarke, W. P. (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Molecular Pharmacology, 54, 94-104.
10. Bohm, S. K., Grady, E. F. and Bunnett, N. W. (1997) Regulatory mechanisms that modulate signalling by G protein-coupled receptors. Biochemical Journal, 322, 1-18.
11. Bottari, S., Vauquelin, G., Durieu, O., Klutchko, C. and Strosberg, A. D. (1979) The [beta]- adrenergic receptor of turkey erythrocyte membranes: Conformational modification by [beta]-adrenergic agonists. Biochemical and Biophysical Research Communications, 86, 1311-1318.
12. Brady, A. E. and Limbird, L. E. (2002) G protein-coupled receptor interacting proteins:emerging roles in localization and signal transduction. Cellular Signalling, 14, 297-309.
13. Brink, C. B., Wade, S. M. and Neubig, R. R. (2000) Agonist-directed trafficking of porcine alpha 2A-adrenergic receptor signaling in Chinese Hamster ovary cells: l-Isoproterenol selectively activates Gs. Journal of Pharmacology and Experimental Therapeutics, 294, 539-547.
14. Burt, A. R., Sautel, M., Wilson, M. A., Rees, S., Wise, A. and Milligan, G. (1998) Agonist occupation of an alpha 2A-Adrenoreceptor-Gi1alpha fusion protein results in activation of both receptor-linked and endogenous Gi proteins. Comparisons of their contributions to GTPase activity and signal transduction and analysis of receptor-G protein activation stoichiometry. Journal of Biological Chemistry, 273, 10367-10375.
15. Buscher, R., Herrmann, V. and Insel, P. A. (1999) Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Trends in Pharmacological Sciences, 20, 94-99.
16. Carter, P. H., Petroni, B. D., Gensure, R. C., Schipani, E., Potts, J. T. Jr. and Gardella, T. J. (2001) Selective and non-selective inverse agonists for constitutively active type-1 parathyroid hormone receptors: evidence for altered receptor conformations. Endocrinology, 142, 1534-1545.
17. Chakrabarti, S., Prather, P. L., Yu, L., Law, P. Y. and Loh, H. H. (1995) Expression of the mu-opioid receptor in CHO cells: Ability of mu-opioid ligands to promote alphaazidoanilido [32P]GTP labeling of multiple G protein alpha subunits. Journal of Neurochemistry, 64, 2534-2543.
18. Chalmers, D. T. and Behan, D. P. (2002) The use of constitutively active GPCRs in drug discovery and functional genomics. Nature Reviews Drug Discovery, 1, 599-608.
19. Cheng, Y. and Prusoff, W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology, 22, 3099-3108.
20. Chidiac, P., Hebert, T., Valiquette, M., Dennis, M. and Bouvier, M. (1994) Inverse agonist activity of beta-adrenergic antagonists. Molecular Pharmacology, 45, 490-499.
21. Christopoulos, A. (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Reviews Drug Discovery, 1, 198-210.
22. Christopoulos, A. and Kenakin, T. (2002) G protein-coupled receptor allosterism and complexing. Pharmacological Reviews, 54, 323-374.
23. Chuang, T. T., Iacovelli, L., Sallese, M. and De Blasi, A. (1996) G protein-coupled receptors:heterologous regulation of homologous desensitization and its implications. Trends in Pharmacological Sciences, 17, 416-421.
24. Cooper, G. M. (2007) The Cell: A Molecular Approach. ASM Press, Washington D.C.
25. Copeland, R., Pompliano, D. and Meek, T. (2006) Drug-target residence time and its implication for lead optimization. Nature Reviews Drug Discovery, 9, 730-739.
26. De Lean, A., Stadel, J. and Lefkowitz, R. (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. Journal of Biological Chemistry, 255, 7108-7117.
27. De Vos, H., Czerwiec, E., De Backer, J. P., De Potter, W. and Vauquelin, G. (1991) [3H]Rauwolscine behaves as an antagonist for the 5-HT(1A) receptors in human frontal cortex membranes. European Journal of Pharmacology-Molecular Pharmacology Section, 207, 1-8.
28. De Vos, H., De Backer, J. P., Convents, A., De Keyser, J. and Vauquelin, G. (1992) Identification of alpha 2 adrenoceptors in the human nucleus olivarius by radioligand binding. Progress in Histochemistry and Cytochemistry, 26, 259-265.
29. Eason, M., Jacinto, M. and Liggett, S. (1994) Contribution of ligand structure to activation of alpha 2-adrenergic receptor subtype coupling to Gs. Molecular Pharmacology, 45, 696-702.
30. Feng, Y.-H., Noda, K., Saad, Y., Liu, X.-P., Husain, A. and Karnik, S. S. (1995) The docking of Arg of angiotensin II with Asp of AT receptor is essential for full agonism. Journal of Biological Chemistry, 270, 12846-12850.
31. Ferguson, S. S. G. (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacological Reviews, 53, 1-24.
32. Fierens, F., Vanderheyden, P. M., De Backer, J. P. and Vauquelin, G. (1999a) Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected Chinese hamster ovary cells. European Journal of Pharmacology, 367, 413-422.
33. Fierens, F. L., Vanderheyden, P. M., De Backer, J. P. and Vauquelin, G. (1999b) Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. European Journal of Pharmacology, 372, 199-206.
34. Fierens, F. L. P., Vanderheyden, P. M. L., Roggeman, C., Vande Gucht, P., De Backer, J.-P. and Vauquelin, G. (2002) Distinct binding properties of the AT1 receptor antagonist [3H]candesartan to intact cells and membrane preparations. Biochemical Pharmacology, 63, 1273-1279.
35. Fischman, A. J., Bonab, A. A., Babich, J. W., Alpert, N. M., Rauch, S. L., Elmaleh, D. R., Shoup, T. M., Williams, S. A. and Rubin, R. H. (1996) Positron emission tomographic analysis of central 5- hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. Journal of Pharmacology and Experimental Therapeutics, 279, 939-947.
36. Flower, D. R. (1999) Modelling G protein-coupled receptors for drug design. Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes, 1422, 207-234.
37. Foord, S. M., Jupe, S. and Holbrook, J. (2002) Bioinformatics and type II G protein-coupled receptors. Biochemical Society Transactions, 30, 473-479.
38. Freissmuth, M., Selzer, E. and Schutz, W. (1991) Interactions of purified bovine brain A1- adenosine receptors with G proteins. Reciprocal modulation of agonist and antagonist binding. Biochemical Journal, 275, 651-656.
39. Frimurer, T.M., and Bywater, B. R. (1999) Structure of the integral membrane domain of the GLP1 receptor proteins. Structure, Function and Genetics, 35, 375-386.
40. Furchgott, R. R. (1966) On the use of -haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In N. J. Harper and A. B. Simmonds, Eds. Advances in Drug Research, Vol 3. Academic Press, London, p. 21-55.
41. Gaborik, Z., Szaszak, M., Szidonya, L., Balla, B., Paku, S., Catt, K. J., Clark, A. J. L. and Hunyady, L. (2001) Beta-arrestin- and dynamin-dependent endocytosis of the AT1 angiotensin receptor. Molecular Pharmacology, 59, 239-247.
42. Gether, U. (2000) Uncovering molecular mechanisms involved in activation of G proteincoupled receptors. Endocrine Review, 21, 90-113.
43. Gether, U. and Kobilka, B. K. (1998) G protein-coupled Receptors. II. Mechanism of agonist activation. Journal of Biological Chemistry, 273, 17979-17982.
44. Gouldson, P. R., Snell, C. R. and Reynolds, C. A. (1997) A new approach to docking in the sdrenergic receptor that exploits the domain structure of G protein-coupled receptors. Journal of Medicinal Chemistry, 40, 3871-3886.
45. Graeser, D. and Neubig, R. (1993) Compartmentation of receptors and guanine nucleotidebinding proteins in NG108-15 cells: lack of cross talk in agonist binding among the alpha 2-adrenergic, muscarinic, and opiate receptors. Molecular Pharmacology, 43, 434-443.
46. Hall, D. (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Molecular Pharmacology, 58, 1412-1423.
47. Hedlund, P., Carson, M., Sutcliffe, J. and Thomas, E. (1999) Allosteric regulation by oleamid of the binding properties of 5-hydroxytryptamine 7 receptors. Biochemical Pharmacology, 58, 1807-1813.
48. Hermans, E. (2003) Biochemical and pharmacological control of the multiplicity of coupling at G protein-coupled receptors. Pharmacology and Therapeutics, 99, 25-44.
49. Holloway, A. C., Qian, H., Pipolo, L., Ziogas, J., Miura, S.-I., Karnik, S., Southwell, B. R., Lew, M. J. and Thomas, W. G. (2002) Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Molecular Pharmacology, 61, 768-777.
50. Holmberg, C. I., Kukkonen, J. P., Bischoff, A., Nasman, J., Courtney, M. J., Michel, M. C. and Akerman, K. E. O. (1998) [alpha]2B-Adrenoceptors couple to Ca2+ increase in both endogenous and recombinant expression systems. European Journal of Pharmacology, 363, 65-74.
51. Hulme, E., Lu, Z., Ward, S., Allman, K. and Curtis, C. (1999) The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. European Journal of Pharmacology, 375, 247-260.
52. Jakubik, J., Bacakova, L., Lisa, V., El-Fakahany, E. E. and Tucek, S. (1996) Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proceedings of the National Academy of Sciences, 93, 8705-8709.
53. Juaneda, C., Dumont, Y. and Quirion, R. (2000) The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends in Pharmacological Sciences, 21, 432-438.
54. Karpa, K. D., Lin, R., Kabbani, N. and Levenson, R. (2000) The dopamine D3 receptor interacts with itself and the truncated D3 splice variant D3nf: D3-D3nf interaction causes mislocalization of D3 receptors. Molecular Pharmacology, 58, 677-683.
55. Kenakin, T. (1995a) Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity. Trends in Pharmacological Sciences, 16, 188-192.
56. Kenakin, T. (1995b) Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends in Pharmacological Sciences, 16, 232-238.
57. Kenakin, T. (1995c) Pharmacological proteus? Trends in Pharmacological Sciences, 16, 256-258.
58. Kenakin, T. (1996) The classification of seven transmembrane receptors in recombinant expression systems. Pharmacological Reviews, 48, 413-463.
59. Kenakin, T. (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends in Pharmacological Sciences, 24, 346-354.
60. Kenakin, T. (2004) Principles: receptor theory in pharmacology. Trends in Pharmacological Sciences, 25, 186-192.
61. Kilpatrick, G. J., Dautzenberg, F. M., Martin, G. R. and Eglen, R. M. (1999) 7TM receptors: the splicing on the cake. Trends in Pharmacological Sciences, 20, 294-301.
62. Kjelsberg, M., Cotecchia, S., Ostrowski, J., Caron, M. & Lefkowitz, R. (1992) Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. Journal of Biological Chemistry, 267, 1430-1433.
63. Koshland, D. E., Jr., Nemethy, G. and Filmer, D. (1966) Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry, 5, 365-385.
64. Kraulis, P. J., Domaille, P. J., Campbell-Burk, S. L., Van Aken, T. and Laue, E. D. (1994) Solution structure and dynamics of Ras p21.GDP determined by heteronuclear three- and four-dimensional NMR spectroscopy. Biochemistry, 33, 3515-3531.
65. Krumins, A. M. and Barber, R. (1997) The stability of the agonist beta 2-adrenergic receptor-Gs complex: evidence for agonist-specific states. Molecular Pharmacology, 52, 144-154.
66. Kukkonen, J. P., Nasman, J. and Akerman, K. E. O. (2001) Modelling of promiscuous receptor-Gi/Gs-protein coupling and effector response. Trends in Pharmacological Sciences, 22, 616-622.
67. Kyte, J. and Doolittle, R. F. (1982) A simple method for displaying the hydropathic character of a protein. Journal of Molecular Biology, 157, 105-132.
68. Le, M. T., Vanderheyden, P. M. L., Szaszak, M., Hunyady, L. and Vauquelin, G. (2002) Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N- and C-terminal residues of angiotensin II during AT1 receptor activation. Journal of Biological Chemistry, 277, 23107-23110.
69. Lee, S. P., O'dowd, B. F., Ng, G. Y. K., Varghese, G., Akil, H., Mansour, A., Nguyen, T. and George, S. R. (2000) Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell. Molecular Pharmacology, 58, 120-128.
70. Leff, P., Scaramellini, C., Law, C. and Mckechnie, K. (1997) A three-state receptor model of agonist action. Trends in Pharmacological Sciences, 18, 355-362.
71. Leppik, R., Lazareno, S., Mynett, A. and Birdsall, N. (1998) Characterization of the allosteric interactions between and amiloride analogues at the human alpha2-adrenergic receptor. Molecular Pharmacology, 53, 916-925.
72. Litschig, S., Gasparini, F., Rueegg, D., Stoehr, N., Flor, P. J., Vranesic, I., Prezeau, L., Pin, J.-P., Thomsen, C. and Kuhn, R. (1999) CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Molecular Pharmacology, 55, 453-461.
73. Luttrell, L. M. and Lefkowitz, R. J. (2002) The role of beta-arrestins in the termination and transduction of G protein-coupled receptor signals. Journal of Cell Science, 115, 455-465.
74. Mallee, J., Salvatore, C., Lebourdelles, B., Oliver, K., Longmore, J., Koblan, K. and Kane, S. (2002) Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. Journal of Biological Chemistry, 277, 14294-14298.
75. McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G. and Foord, S. M. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature, 393, 333-339.
76. Meng, E. C. and Bourne, H. R. (2001) Receptor activation: what does the rhodopsin structure tell us? Trends in Pharmacological Sciences, 22, 587-593.
77. Mhaouty-Kodja, S., Barak, L. S., Scheer, A., Abuin, L., Diviani, D., Caron, M. G. and Cotecchia, S. (1999) Constitutively active alpha-1b adrenergic receptor mutants display different phosphorylation and internalization features. Molecular Pharmacology, 55, 339-347.
78. Mijares, A., Lebesgue, D., Wallukat, G. and Hoebeke, J. (2000) From agonist to antagonist:fab fragments of an agonist-like monoclonal anti-beta 2-adrenoceptor antibody behave as antagonists. Molecular Pharmacology, 58, 373-379.
79. Milligan, G. (2003) Principles: extending the utility of [35S]GTP gamma S binding assays. Trends in Pharmacol Sciences, 24, 87-91.
80. Milligan, G. and White, J. H. (2001) Protein-protein interactions at G protein-coupled receptors. Trends in Pharmacological Sciences, 22, 513-518.
81. Mohler, H. and Fritschy, J.-M. (1999) GABAB receptors make it to the top-as dimers. Trends in Pharmacological Sciences, 20, 87-89.
82. Monod, J., Wyman, J. and Changeux, J. (1965) On the nature of allosteric transitions: a plausible model. Journal of Molecular Biology, 12, 88-118.
83. Montgomery, R., Conway, T. W. and Spector, A. A. (1990) Biochemistry. A Case-Oriented Approach. The C.V. Mosby Company, St. Louis.
84. Morfis, M., Christopoulos, A. and Sexton, P. M. (2003) RAMPs: 5 years on, where to now? Trends in Pharmacological Sciences, 24, 596-601.
85. Nasman, J., Kukkonen, J. P., Ammoun, S. and Akerman, K. E. O. (2001) Role of G protein availability in differential signaling by alpha 2-adrenoceptors. Biochemical Pharmacology, 62, 913-922.
86. Nelson, D. L. and Cox, M. M. (2000) Principles of Biochemistry. New York, Freeman and Company.
87. Nelson, D. L. and Cox, M. M. (2005) Lehninger, Principles of Biochemistry. New York, W. H. Freeman and Company, p. 372.
88. Oh, P. and Schnitzer, J. E. (2001) Segregation of heterotrimeric G proteins in cell surface microdomains. Gq binds caveolin to concentrate in caveolae, whereas Gi and Gs target lipid rafts by default. Molecular Biology of the Cell, 12, 685-698.
89. Okamoto, T., Schlegel, A., Scherer, P. E. and Lisanti, M. P. (1998) Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. Journal of Biological Chemistry, 273, 5419-5422.
90. Ostrom, R. S. (2002) New determinants of receptor-effector coupling: trafficking and compartmentation in membrane microdomains. Molecular Pharmacology, 61, 473-476.
91. Ostrom, R. S., Gregorian, C., Drenan, R. M., Xiang, Y., Regan, J. W. and Insel, P. A. (2001) Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. Journal of Biological Chemistry, 276, 42063-42069.
92. Ostrom, R. S., Post, R. and Insel, P. (2000) Stochiometry and compartmentation in G protein-coupled receptor signaling: implications for therapetic interventions involving G(s). Journal of Pharmacology and Experimental Therapeutics, 294, 407-412.
93. Ostrowski, J., Kjelsberg, M., Caron, M. and Lefkowitz, R. (1992) Mutagenesis of the beta-2 adrenergic receptor: how structure elucidates function. Annual Review of Pharmacology and Toxicology, 32, 162-183.
94. Parnot, C., Bardin, S., Miserey-Lenkei, S., Guedin, D., Corvol, P. and Clauser, E. (2000) Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay. Proceedings of the National Academy of Sciences, 97, 7615-7620.
95. Parnot, C., Miserey-Lenkei, S., Bardin, S., Corvol, P. and Clauser, E. (2002) Lessons from constitutively active mutants of G protein-coupled receptors. Trends in Endocrinology and Metabolism, 13, 336-343.
96. Pellegrini-Giampietro, D. E. (2003) The distinct role of mGlu1 receptors in post-ischemic neuronal death. Trends in Pharmacological Sciences, 24, 461-470.
97. Pike, L. J. (2003) Lipid rafts: bringing order to chaos. Journal of Lipid Research, 44, 655-667.
98. Pin, J.-P., Galvez, T. and Prezeau, L. (2003) Evolution, structure, and activation mechanism of family 3/C G protein-coupled receptors. Pharmacology & Therapeutics, 98, 325-354.
99. Pommier, B., Da Nascimento, S., Dumont, S., Bellier, B., Million, E., Garbay, C., Roques, B. P. and Noble, F. (1999) The cholecystokinin B receptor is coupled to two effector pathways through pertussis toxin-sensitive and -insensitive G proteins. Journal of Neurochemistry, 73, 281-288.
100. Ramsay, D., Kellett, E., Mcvey, M., Rees, S. and Milligan, G. (2002) Homo- and hetero-oligomeric interactions between G protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochemical Journal, 365, 429-440.
101. Reader, A. J. and Zweit, J. (2001) Developments in whole-body molecular imaging of live subjects. Trends in Pharmacological Sciences, 22, 604-607.
102. Rhoades, R. A. and Tanner, G. A. (1995) Medical Physiology. Philadelphia, Lipincott Williams & Wilkins (A Wolters Kluwer Company), p.49 (Fi.g 3-20 A).
103. Rios, C. D., Jordan, B. A., Gomes, I. and Devi, L. A. (2001) G protein-coupled receptor dimerization:modulation of receptor function. Pharmacology and Therapeutics, 92, 71-87.
104. Rocheville, M., Lange, D., Kumar, U., Sasi, R., Patel, R. and Patel, Y. (2000) Subtypes of the somatostatain receptor assemble as functional homo- and heterodimers. Journal of Biological Chemistry, 11, 7869-7869.
105. Samama, P., Cotecchia, S., Costa, T. and Lefkowitz, R. (1993) A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. Journal of Biological Chemistry, 268, 4625-4636.
106. Scatchard, G. (1949) The attraction of proteins to small molecules and ions. Annals of the New York Academy of Sciences, 51, 600-672.
107. Schwartz, T., Gether, U., Schambye, H. and Hjort, T. (1995) Molecular mechanism of action of non-peptide ligands for peptide receptors. Current Pharmaceutical Design, 1, 325-342.
108. Seeley, R. R., Stephens,T.D. and Tate, P. (2000) Anatomy & Physiology. Boston, McGraw Hill.
109. Singer, S. J. and Nicolson, G. L. (1972) The fluid mosaic model of the structure of cell membranes. Science, 175, 720-731.
110. Solomon, K. R., Adolphson, L. D., Wank, D. A., Mchugh, K. P. and Hauschka, P. V. (2000) Caveolae in human and murine osteoblasts. Journal of Bone & Mineral Research, 15, 2391-2401.
111. Sprengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburgt, P. H. and Journot, L. (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature, 365, 170-175.
112. Stacey, M., Lin, H.-H., Gordon, S. and Mcknight, A. J. (2000) LNB-TM7, a group of seven-transmembrane proteins related to family-B G protein-coupled receptors. Trends in Biochemical Sciences, 25, 284-289.
113. Stephenson, R. P. (1956) A modification of receptor theory. British Journal of Pharmacology and Chemotherapy, 11, 379-393.
114. Strosberg, A. D. (1987) The beta-adrenergic receptors and G proteins in The Molecular Biology of Receptor Techniques and Applications of Receptor Research. Weinheim, VCH Publisher, p. 139-163.
115. Subramaniam, S. and Hendersson, R. (2000) Crystallographic analysis of protein conformational changes in the bacteriorhodopsin photocycle. Biochimica et Biophysica Acta, 1460, 157-165.
116. Sutherland, E. W. and Robison, G. A. (1966) The role of cyclic-3',5'-AMP in responses to catecholamines and other hormones. Pharmacological Reviews, 18, 145-161.
117. Swinney, D. (2004) Biochemical mechanisms of drug action: what does it take for success. Nature Reviews Drug Discovery, 3, 801-808.
118. Thomas, W. G. and Qian, H. (2003) Arresting angiotensin type 1 receptors. Trends in Endocrinology & Metabolism, 14, 130-136.
119. Tian, W. N., Duzic, E., Lanier, S. M. and Deth, R. C. (1994) Determinanans of alpha 2- adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G proetin state. Molecular Pharmacology, 45, 524-531.
120. Tohgo, A., Choy, E. W., Gesty-Palmer, D., Pierce, K. L., Laporte, S., Oakley, R. H., Caron, M.G., Lefkowitz, R. J. & Luttrell, L. M. (2003) The stability of the G protein-coupled receptorbeta -arrestin interaction determines the mechanism and functional consequence of ERK activation. Journal of Biological Chemistry, 278, 6258-6267.
121. Tohgo, A., Pierce, K. L., Choy, E. W., Lefkowitz, R. J. and Luttrell, L. M. (2002) beta -Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. Journal of Biological Chemistry, 277, 9429-9436.
122. Tolkovsky, A. and Levitzki, R. (1978) Model of coupling between the beta-adrenergic receptor and adnylate cyclase in turkey erythrocyte membranes. Biochemistry, 17, 3795-3810.
123. Torrens, Y., Beaujouan, J.-C., Saffroy, M. and Glowinski, J. (2000) Further evidence for the presence of "septide-sensitive" tachykinin binding sites in tissues possessing solely NK1 tachykinin receptors. Biochemical and Biophysical Research Communications, 270, 665-672.
124. Urwyler, S., Mosbacher, J., Lingenhoehl, K., Heid, J., Hofstetter, K., Froestl, W., Bettler, B. and Kaupmann, K. (2001) Positive allosteric modulation of native and recombinant gamma -aminobutyric acid B receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Molecular Pharmacology, 60, 963-971.
125. Van Liefde, I., Van Witzenburg, A. and Vauquelin, G. (1992) Multiple beta adrenergic receptor subclasses mediate the l-isoproterenol-induced lipolytic response in rat adipocytes. Journal of Pharmacology and Experimental Therapeutics, 262, 552-558.
126. Van Liefde, I., Vanderheyden, P. M. L., Fraeyman, N., De Backer, J. P. and Vauquelin, G. (1998) Human neuropeptide YY1 receptors exert unequal control of the extracellular acidification rate in different cell lines. European Journal of Pharmacology, 346, 87-95.
127. Vanderheyden, P. M. L., Fierens, F. L. P., De Backer, J. P., Fraeyman, N. and Vauquelin, G. (1999) Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors. British Journal of Pharmacology, 126, 1057-1065.
128. Vauquelin, G., Bottari, S. and Strosberg, A. D. (1980) Inactivation of beta-adrenergic receptors by N-ethylmalmeimide: permissive role of beta-adrenergic agents in relation to adenylate cyclase activation. Molecular Pharmacology, 17, 163-171.
129. Vauquelin, G, DeVos, H., De Backer, J.P. and Ebinger, G (1990) Identification of alpha2 adrenergic receptors in human frontal cortex membranes by binding of [3H]RX 821002, the 2-methoxy analog of [3H]idazoxan. Neurochemistry International, 17, 537-546.
130. Vauquelin, G., Fierens, F. and Vanderheyden, P. (2002) Mechanisms of Angiotensin II Antagonism. Competitive vs. Non-Competitive Inhibition in Angiotensin II Receptor Antagonists. Philadelphia, Harley & Belfus Inc., p. 105-118.
131. Vauquelin, G., Severne, Y., Convents, A., Nerme, V. and Abrahamsson, T. (1988) Agonistmediated activation of adrenergic receptors. In C. Melchiorre andM. Gianella, Eds. Recent Advances in Receptor Chemistry. Amsterdam, Elsevier Science Publishers B.V., p. 43-61.
132. Vauquelin, G. and Van Liefde, I. (2005) G protein-coupled receptors: a count of 1001 conformations. Fundamental and Clinical Pharmacology, 19, 45-56.
133. Wallukat, G., Wollenberger, A., Morwinski, R. and Pitschner, H. F. (1995) Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. Journal of Molecular & Cellular Cardiology, 27, 397-406.
134. Wang, Q. and Limbird, L. E. (2002) Regulated interactions of the alpha 2A adrenergic receptor with spinophilin, 14-3-3zeta, and arrestin 3. Journal of Biological Chemistry, 277, 50589-50596.
135. Weiss, J. M., Morgan, P. H., Lutz, M. W. and Kenakin, T. P. (1996) The cubic ternary complex receptor-occupancy model III. Resurrecting efficacy. Journal of Theoretical Biology, 181, 381-397.
136. Wenzel-Seifert, K. and Seifert, R. (2000) Molecular analysis of beta 2-adrenoceptor coupling to Gs-, Gi-, and Gq-proteins. Molecular Pharmacology, 58, 954-966.
137. Wess, J. (1998) Molecular basis of receptor/G protein-coupling selectivity. Pharmacology and Therapeutics, 80, 231-264.
138. Willets, J. M., Challiss, R. A. J. and Nahorski, S. R. (2003) Non-visual GRKs: are we seeing the whole picture? Trends in Pharmacological Sciences, 24, 626-633.
139. Wingard, L. B., Brody, T. M., Larner, J. and Schwartz, A. (1991) Human Pharmacology: Molecular to Clinical. London, Wolfe Publishing Ltd., p. 234 (Fig. 18-2).
140. Wurch, T. and Pauwels, P. J. (2001) Analytical pharmacology of G protein-coupled receptors by stoichiometric expression of the receptor and G(alpha) protein subunits. Journal of Pharmacological and Toxicological Methods, 45, 3-16.
141. Yeagle, P. L. and Albert, A. D. (2003) A conformational trigger for activation of a G protein by a G protein-coupled receptor. Biochemistry, 42, 1365-1368.
142. Zubay (1993) Biochemistry, Volume two: Catabolism and Biosynthesis. Oxford, Wim. C. Brown Publishers, p. 667 (Part of Table 24.3).